Close

ITK

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This gene encodes an intracellular tyrosine kinase expressed in T-cells. The protein contains both SH2 and SH3 domains which are often found in intracellular kinases. The protein Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR receptor, where it is phosphorylated by LCK.
  • CAR Vector Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-CN029 Anti-ITK (12A9) h(CD28-CD3ζ) CAR, pCDCAR1 Human 12A9 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN030 Anti-ITK (12B1) h(CD28-CD3ζ) CAR, pCDCAR1 Human 12B1 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN031 Anti-ITK (12F4) h(CD28-CD3ζ) CAR, pCDCAR1 Human 12F4 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN032 Anti-ITK (14G9) h(CD28-CD3ζ) CAR, pCDCAR1 Human 14G9 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN033 Anti-ITK (14H5) h(CD28-CD3ζ) CAR, pCDCAR1 Human 14H5 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN034 Anti-ITK (16C12) h(CD28-CD3ζ) CAR, pCDCAR1 Human 16C12 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN035 Anti-ITK (18H8) h(CD28-CD3ζ) CAR, pCDCAR1 Human 18H8 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN036 Anti-ITK (3A8) h(CD28-CD3ζ) CAR, pCDCAR1 Human 3A8 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN130 Anti-ITK (12A9) h(41BB-CD3ζ) CAR, pCDCAR1 Human 12A9 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN131 Anti-ITK (12B1) h(41BB-CD3ζ) CAR, pCDCAR1 Human 12B1 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN132 Anti-ITK (12F4) h(41BB-CD3ζ) CAR, pCDCAR1 Human 12F4 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN133 Anti-ITK (14G9) h(41BB-CD3ζ) CAR, pCDCAR1 Human 14G9 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN134 Anti-ITK (14H5) h(41BB-CD3ζ) CAR, pCDCAR1 Human 14H5 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN135 Anti-ITK (16C12) h(41BB-CD3ζ) CAR, pCDCAR1 Human 16C12 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN136 Anti-ITK (18H8) h(41BB-CD3ζ) CAR, pCDCAR1 Human 18H8 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CN137 Anti-ITK (3A8) h(41BB-CD3ζ) CAR, pCDCAR1 Human 3A8 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.